Second phase III trial of dasiglucagon for the treatment of congenital hyperinsulinism

Trial Profile

Second phase III trial of dasiglucagon for the treatment of congenital hyperinsulinism

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Dasiglucagon
  • Indications Hyperinsulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2018 New trial record
    • 19 Jan 2018 According to a Zealand Pharma media release, FDA has approved the Investigational New Drug (IND) application for the phase 3 program. Two Phase 3 trials are expected to begin in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top